Neha Singh

Neha Singh

Auto-generated profile, based on publicly available information

Neha Singh

University of Arizona Cancer Center University of Arizona Tucson AZ USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
NSNeha Singh
Neha Singh
VRVarune R. Ramnarine
Varune R. Ramnarine
JSJin H. Song
Jin H. Song
RPRitu Pandey
Ritu Pandey
SPSathish K. R. Padi
Sathish K. R. Padi
AKAndrew S. Kraft
Andrew S. Kraft
Neuroendocrine (NE) prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (PCa) arising either de novo or from transdifferentiated prostate adenocarcinoma following androgen deprivation therapy (ADT). Extensive computational analysis has identified a high degree of association between the long noncoding RNA (lncRNA) H19 and NEPC, with the longest isoform highly expressed in NEPC. H19 regulates PCa lineage plasticity by driving a bidirectional cell identity of NE phenotype (H19 overexpression) or luminal phenotype (H19 knockdown). It contributes to treatment resistance, with the knockdown of H19 re-sensitizing PCa to ADT. It is also essential for the proliferation and invasion of NEPC. H19 levels are negatively regulated by androgen signaling via androgen receptor (AR). When androgen is absent SOX2 levels increase, driving H19 transcription and facilitating transdifferentiation. H19 facilitates the PRC2 complex in regulating methylation changes at H3K27me3/H3K4me3 histone sites of AR-driven and NEPC-related genes. Additionally, this lncRNA induces alterations in genome-wide DNA methylation on CpG sites, further regulating genes associated with the NEPC phenotype. Our clinical data identify H19 as a candidate diagnostic marker and predictive marker of NEPC with elevated H19 levels associated with an increased probability of biochemical recurrence and metastatic disease in patients receiving ADT. Here we report H19 as an early upstream regulator of cell fate, plasticity, and treatment resistance in NEPC that can reverse/transform cells to a treatable form of PCa once therapeutically deactivated.

1 December 2018 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JSJin H Song
Jin H Song
NSNeha Singh
Neha Singh
LLLibia A. Luevano
Libia A. Luevano
SPSathish K.R. Padi
Sathish K.R. Padi
KOKoichi Okumura
Koichi Okumura
AKAndrew S. Kraft
Andrew S. Kraft
Cancer resistance to PI3K inhibitor therapy can be in part mediated by increases in the PIM1 kinase. However, the exact mechanism by which PIM kinase promotes tumor cell resistance is unknown. Our study unveils the pivotal control of redox signaling by PIM kinases as a driver of this resistance mechanism. PIM1 kinase functions to decrease cellular ROS levels by enhancing nuclear factor erythroid 2-related factor 2 (NRF2)/antioxidant response element activity. PIM prevents cell death induced by PI3K-AKT–inhibitory drugs through a noncanonical mechanism of NRF2 ubiquitination and degradation and translational control of NRF2 protein levels through modulation of eIF4B and mTORC1 activity. Importantly, PIM also controls NAD(P)H production by increasing glucose flux through the pentose phosphate shunt decreasing ROS production, and thereby diminishing the cytotoxicity of PI3K-AKT inhibitors. Treatment with PIM kinase inhibitors reverses this resistance phenotype, making tumors increasingly susceptible to small-molecule therapeutics, which block the PI3K-AKT pathway.

1 January 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ACAndrea L. Casillas
Andrea L. Casillas
RTRachel K. Toth
Rachel K. Toth
ASAlva G. Sainz
Alva G. Sainz
NSNeha Singh
Neha Singh
ADAnkit A. Desai
Ankit A. Desai
NWNoel Warfel
Noel Warfel
Purpose: Patients develop resistance to antiangiogenic drugs, secondary to changes in the tumor microenvironment, including hypoxia. PIM kinases are prosurvival kinases and their expression increases in hypoxia. The goal of this study was to determine whether targeting hypoxia-induced PIM kinase expression is effective in combination with VEGF-targeting agents. The rationale for this therapeutic approach is based on the fact that antiangiogenic drugs can make tumors hypoxic, and thus more sensitive to PIM inhibitors. Experimental Design: Xenograft and orthotopic models of prostate and colon cancer were used to assess the effect of PIM activation on the efficacy of VEGF-targeting agents. IHC and in vivo imaging were used to analyze angiogenesis, apoptosis, proliferation, and metastasis. Biochemical studies were performed to characterize the novel signaling pathway linking PIM and HIF1. Results: PIM was upregulated following treatment with anti-VEGF therapies, and PIM1 overexpression reduced the ability of these drugs to disrupt vasculature and block tumor growth. PIM inhibitors reduced HIF1 activity, opposing the shift to a pro-angiogenic gene signature associated with hypoxia. Combined inhibition of PIM and VEGF produced a synergistic antitumor response characterized by decreased proliferation, reduced tumor vasculature, and decreased metastasis. Conclusions: This study describes PIM kinase expression as a novel mechanism of resistance to antiangiogenic agents. Our data provide justification for combining PIM and VEGF inhibitors to treat solid tumors. The unique ability of PIM inhibitors to concomitantly target HIF1 and selectively kill hypoxic tumor cells addresses two major components of tumor progression and therapeutic resistance. Clin Cancer Res; 24(1); 169–80. ©2017 AACR.

15 February 2021 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
JBJeremiah J Bearss
Jeremiah J Bearss
SPSathish Kr Padi
Sathish Kr Padi
NSNeha Singh
Neha Singh
MCMarina Cardo-Vila
Marina Cardo-Vila
JSJin H Song
Jin H Song
KOKoichi Okumura
Koichi Okumura

17 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
SPSathish K.R. Padi
Sathish K.R. Padi
LLLibia A. Luevano
Libia A. Luevano
NANingfei An
Ningfei An
RPRitu Pandey
Ritu Pandey
NSNeha Singh
Neha Singh
AKAndrew S. Kraft
Andrew S. Kraft
Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset

15 November 2015 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
NSNeha Singh
Neha Singh
SJShrinidh Joshi
Shrinidh Joshi
LGLirong Guo
Lirong Guo
MBMatthew B. Baker
Matthew B. Baker
YLYan Li
Yan Li
YJYagna P. R. Jarajapu
Yagna P. R. Jarajapu
CD34+stem/progenitor cells have been identified as a promising cell population for the autologous cell-based therapies in patients with cardiovascular disease. The counter-regulatory axes of renin angiotensin system, angiotensin converting enzyme (ACE)/Ang II/angiotensin type 1 (AT1) receptor and ACE2/Ang-(1–7)/Mas receptor, play an important role in the cardiovascular repair. This study evaluated the expression and vascular repair-relevant functions of these two pathways in human CD34+cells. CD34+cells were isolated from peripheral blood mononuclear cells (MNCs), obtained from healthy volunteers. Expression of ACE, ACE2, AT1, and angiotensin type 2 and Mas receptors were determined. Effects of Ang II, Ang-(1–7), Norleu3-Ang-(1–7), and ACE2 activators, xanthenone (XNT) and diminazene aceturate (DIZE) on proliferation, migration, and adhesion of CD34+cells were evaluated. ACE2 and Mas were relatively highly expressed in CD34+cells compared with MNCs. Ang-(1–7) or its analog, Norleu3-Ang-(1–7), stimulated proliferation of CD34+cells that was associated with decrease in phosphatase and tensin homologue deleted on chromosome 10 levels and was inhibited by triciribin, an AKT inhibitor. Migration of CD34+cells was enhanced by Ang-(1–7) or Norleu3-Ang-(1–7) that was decreased by a Rho-kinase inhibitor, Y-27632. In the presence of Ang II, XNT or DIZE enhanced proliferation and migration that were blocked by DX-600, an ACE2 inhibitor. Treatment of MNCs with Ang II, before the isolation of CD34+cells, attenuated the proliferation and migration to stromal derived factor-1α. This attenuation was reversed by apocynin, an NADPH oxidase inhibitor. Adhesion of MNCs or CD34+cells to fibronectin was enhanced by Ang II and was unaffected by Ang-(1–7). This study suggests that ACE2/Ang-(1–7)/Mas pathway stimulates functions of CD34+cells that are cardiovascular protective, whereas Ang II attenuates these functions by acting on MNCs. These findings imply that activation of ACE2/Ang-(1–7)/Mas axis is a promising approach for enhancing reparative outcomes of cell-based therapies.